Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vaneck Pharmaceutical ETF (NQ: PPH ) 93.64 -0.83 (-0.87%) Streaming Delayed Price Updated: 12:28 PM EDT, Aug 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Vaneck Pharmaceutical ETF Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report June 12, 2024 Novo Nordisk is challenging Lego A/S for the title of Denmark's most valuable brand, with its brand value surging 59% to $5.1 billion. This growth is fueled by the global popularity of its weight-loss... Via Benzinga Just Say No to Drugs: 3 Pharma Stocks to Avoid May 08, 2024 Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios. Via InvestorPlace A Look At Pharma ETFs Post Q1 Earnings May 07, 2024 Pharma ETFs have delivered mixed performances over the past month. Via Talk Markets Topics ETFs ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook May 01, 2024 Eli Lilly and Company posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. Investors seeking to tap the opportune moment could bet on ETFs having the largest... Via Talk Markets Topics ETFs 3 Weight-Loss ETFs to Profit From the Obesity Drug Boom April 17, 2024 Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment. Via InvestorPlace Topics ETFs Novo Nordisk's Game-Changer: FDA Approves Weight Loss Sensation Wegovy For Heart Health, Potential Insurance Coverage March 08, 2024 Novo Nordisk's Wegovy receives FDA approval for expanded use, targeting a significant reduction in cardiovascular events and weight management. Via Benzinga Exposures Product Safety The Top 3 ETFs to Buy in March 2024 March 07, 2024 Simplify your investment strategy through these top ETFs to buy, offering an excellent blend of diversification and upside. Via InvestorPlace Topics ETFs 11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields February 28, 2024 A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. Via Benzinga A Look At Pharma ETFs After Q4 Earnings February 12, 2024 The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. Via Talk Markets Topics ETFs 5 ETF Zones Scaling New Highs At The Start Of 2024 January 08, 2024 The start of 2024 has been weak for the global stock market after a blockbuster 2023. Still, a few corners of the stock market are outperforming, pushing ETFs to new 52-week highs. Via Talk Markets Topics ETFs Government-granted Patent Monopolies Are Not The Free Market December 29, 2023 Our system for developing new drugs is a disaster. While we can point to great successes, they come at enormous cost. We will spend over $600B this year on prescription and non-prescription drugs -... Via Talk Markets Topics Intellectual Property Exposures Intellectual Property Preparing For The Next Short-Term Rally Higher August 12, 2023 The short-term downtrend appears set to continue. The market is taking the time it needs to consolidate near its short-term trend lows in order to prepare a base from which it can begin its next... Via Talk Markets Pharma ETFs in Focus Post Q2 Earnings August 11, 2023 Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth. Via Talk Markets Topics ETFs The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023 July 21, 2023 Trading below a 15 forward price-to-earnings, these undervalued pharma stocks offer opportunities in an overbought market. Via InvestorPlace Pharma ETFs Gain Post Q1 Earnings May 09, 2023 Pharma ETFs have been in the green over the past month. Via Talk Markets A Look At Pharma ETFs Post Q4 Earnings February 08, 2023 Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. Via Talk Markets 5 Sector ETFs That Beat The Market In December December 27, 2022 While most segments of the market are suffering from huge losses, a few have performed really well. These are likely to continue outperforming should the trends prevail. Via Talk Markets Pharma ETFs In Focus Post Q3 Earnings November 09, 2022 Many industry bigwigs reported solid results with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. Via Talk Markets Wave of Solid Q3 Earnings Push Pharma ETFs Higher November 09, 2021 The slew of Q3 results has led to smooth trading in pharma ETFs over the past month. Via Talk Markets Pharma ETFs in Focus Post Q1 Earnings May 12, 2021 The slew of Q1 results has led to mixed trading in pharma ETFs over the past month. Here are those in detail. Via Talk Markets Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
